Researchers analyzed data on 100,000+ women over 20-year period
A new study in JAMA Oncology questions whether the treatment administered to tens of thousands of women who are diagnosed annually with ductal carcinoma in situ (DCIS), a very early-stage breast cancer, actually improves their outcomes.
DCIS—also called Stage Zero breast cancer—is a condition in which abnormal cells build up in the milk duct's lining. Diagnoses of DCIS have increased significantly over the past few decades, and now make up nearly 25% of all cancer diagnoses made via mammography. About 60,000 U.S. women are diagnosed with DCIS annually.
The Advisory Board Company